ORIGINAL CONTRIBUTION. Neuropsychologic Status in Multiple Sclerosis After Treatment With Glatiramer
|
|
- Delilah Douglas
- 5 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Neuropsychologic Status in Multiple Sclerosis After Treatment With Glatiramer Amy Weinstein, PhD; Steven I. L. Schwid, MD; Randolph B. Schiffer, MD; Michael P. McDermott, PhD; Daniel W. Giang, MD; Andrew D. Goodman, MD Background: Glatiramer acetate (Copaxone) therapy reduces clinical disease activity in relapsing-remitting multiple sclerosis (MS). Objective: To study the effect of glatiramer therapy on neuropsychologic function as part of a randomized, placebo-controlled, multicenter trial. Methods: Two hundred forty-eight patients with relapsing-remitting MS and mild to moderate disability (Expanded Disability Status Scale score, 5.0) were tested before and 12 and 24 months after randomization to administration of glatiramer acetate, 20 mg/d, or matching placebo. Neuropsychologic tests examined 5 cognitive domains most often disrupted in patients with MS: sustained attention, perceptual processing, verbal and visuospatial memory, and semantic retrieval. Results: Baseline neuropsychologic test performance was similar in both treatment groups and was within normal range, except for impaired semantic retrieval. Mean neuropsychologic test scores were higher at 12 and 24 months than at baseline, and no differences were detected between treatment groups over time. No significant interactions were detected between treatment and either time or baseline impairment. Conclusions: Our 2-year longitudinal study showed no effect of glatiramer therapy on cognitive function in relapsing-remitting MS. Although it is possible that glatiramer therapy has no effect on cognitive function, the lack of measurable decline in cognitive function in both patient groups for 2 years limits the opportunity for glatiramer to demonstrate a therapeutic effect by minimizing such decline. Emerging treatments for MS should continue to be examined for their effect on cognitive impairment because it can be a critical determinant of disability. A greater understanding of the natural history of cognitive decline in MS is essential for a rational design of these drug trials. Arch Neurol. 1999;56: From the Departments of Neurology (Drs Weinstein, Schwid, Schiffer, McDermott, and Goodman), Psychiatry (Drs Weinstein and Schiffer), Environmental Medicine (Dr Schiffer), and Biostatistics (Dr McDermott), University of Rochester Medical Center, Rochester, NY; and the Department of Neurology, Loma Linda University Medical Center, Loma Linda, Calif (Dr Giang). ADOUBLE-BLIND, placebocontrolled, multicenter phase III trial evaluating the efficacy and safety of treatment with glatiramer acetate (Copaxone; Teva Pharmaceutical Industries, Petah Tiqva, Israel), formerly called copolymer 1, for patients with relapsing-remitting multiple sclerosis (MS) was recently completed. 1 Results indicate that glatiramer therapy reduces the MS relapse rate by 29% over 2 years. A trend toward increasing the time to first relapse was also demonstrated, with a median time to relapse of 287 days for patients treated with glatiramer compared with 198 days for patients treated with placebo. More patients treated with glatiramer improved neurologically and fewer worsened on the Expanded Disability Status Scale 2 compared with patients treated with placebo. We report the effect of glatiramer therapy on cognitive function in the same patients. Results of numerous neuropsychologic studies 3-8 demonstrate that up to 65% of patients with MS show impairment in cognitive function during their illness. The most frequently occurring changes in cognitive function are found in measures of recent memory, 7,9-15 sustained attention and speed of cognitive processing, 9,16-18 semantic retrieval, 9,19,20 conceptual/abstract reasoning, 3,6,21,22 andvisuospatialperception. 9,15,19,20,23 Immediateandremotememoryandlanguage skills are the least-disrupted aspects of cognitive functioning. Cognitive changes in MS are not necessarily associated with changes in measures of physical impairment 24 or disease duration. 25,26 For example, results of numerous studies 4,27,28 demonstrate that memory impairment may be observed early in the disease process in the presence of minimal physical disability. Traditional measures of overall neurologic impairment in MS, such as the Expanded Disability Status Scale, are insensitive to the presence of cognitive defi- 319
2 PATIENTS AND METHODS STUDY DESIGN A randomized, double-blind, placebo-controlled, multicenter phase 3 trial studying the effects of glatiramer therapy on MS was conducted at 11 centers in the United States. Two hundred fifty-one patients with relapsing-remitting MS were randomly assigned to receive a regimen of daily subcutaneous injections of glatiramer acetate, 20 mg, or matching placebo and were followed up systematically for 2 years. The primary results of this trial have been published previously. 1 Effects on neuropsychologic outcomes from this study are presented. PATIENTS Patients aged 18 to 45 years with clinically definite MS or laboratory-supported MS who had at least 2 relapses in the 2 years before entry into the study were included. All patients had mild to moderate disability at baseline as defined by an Expanded Disability Status Scale score between 0 and 5.0. As reported previously, the distributions of age, sex, race, duration of disease, mean relapse rate in the previous 2 years, and Expanded Disability Status Scale score were similar in the treatment groups at baseline (Table 1). Nineteen patients (15.2%) withdrew from the glatiramer-treated group and 17 patients (13.5%) withdrew from the placebo-treated group. 1 PROCEDURE Neuropsychologic tests were administered to all patients by trained research coordinators at each of the 11 study sites. Neuropsychologic testing occurred at a screening visit within 1 month before drug initiation and after 12 and 24 months of masked treatment. Tests were presented in the same order at each visit to standardize possible effects of fatigue, with alternate forms used to minimize practice effects. NEUROPSYCHOLOGIC EVALUATION The Brief Repeatable Battery of Neuropsychological Tests was chosen as the measure of cognitive functioning. This battery was developed by the Cognitive Functions Study Group of the National Multiple Sclerosis Society specifically for use in clinical trials of potential MS treatments, with tests chosen because they are sensitive to neuropsychologic deficits common in patients with MS The Brief Repeatable Battery of Neuropsychological Tests requires 20 minutes to administer and can be presented by nonpsychologists after training. It consists of 5 tests, including measures of sustained attention and concentration (Paced Auditory Serial Addition Test and Symbol Digit Modalities Test), verbal learning and delayed recall (Buschke Selective Reminding Test), visuospatial learning and delayed recall (10/36 Spatial Recall Test), and semantic retrieval (Word List Generation Test). Buschke Selective Reminding Test The version of the Selective Reminding Test 37,38 chosen for this study is a 6-trial verbal list learning test 39 designed to measure verbal learning and recall from memory over time. The procedure involves reading the patient a list of 12 words and having the patient recall as many words as possible in any order. In each of the following learning trials, only words not recalled on the preceding trial are presented. The patient is then instructed to continue to recall all words from the list, including those not repeated. After 6 list presentations, delayed recall is tested after an 11-minute delay. Scores are based on consistent long-term retrieval, the number of words recalled consistently on all subsequent trials without reminding; delayed recall, the number of items recalled from the complete list after an 11-minute delay; and long-term storage, the sum of words recalled after 6 repeated trials. cits and to changes in cognition over time. 3 In fact, the natural history of cognitive changes in MS is largely unknown. Cognitive impairment in MS may have a negative impact on vocational and social roles beyond that related to physical disability. 29 Despite equivalent physical disability, patients with MS with cognitive impairment have lower rates of employment, greater withdrawal from social activities, and more extensive need for personal assistance at home because of greater difficulty performing routine household tasks than patients without cognitive impairment. 4,30 Activities of daily living and quality of life are more impaired than predicted by physical disability alone. 8,26,31 Two previous studies 32,33 attempted to determine the effects of drug treatment on neuropsychologic deficits in patients with MS. Pliskin et al 32 examined neuropsychologic function in a randomized trial involving 30 patients with MS after 2 and 4 years of high- or low-dose treatment with interferon beta-1b or placebo. Although there was significant improvement in delayed visual memory between years 2 and 4 of the trial in patients receiving high-dose interferon beta-1b relative to nonsignificant changes in the placebo group, the results are difficult to interpret because baseline assessments were not performed, the sample size was small, and only 1 of several tests performed showed any effect of treatment. Smits et al 33 examined neuropsychologic function in a randomized, double-blind, placebo-controlled, crossover design clinical trial of patients with MS treated with 4-aminopyridine, a potassium channel blocker with the potential to improve conduction through demyelinated pathways. No effect of treatment was detected, but only 20 patients were included, with treatment for only 2 weeks, providing limited power to detect modest effects. Interpretation of this study was also complicated by the use of a crossover design without a washout period. The present investigation is the first large-scale study to determine whether a treatment used to alter the course of MS affects cognitive function. We postulated that cognitive function would measurably decline during the trial and that treatment with glatiramer might minimize that decline. 320
3 10/36 Spatial Recall Test The 10/36 Spatial Recall Test, a more cognitively demanding version of the 7/24 test, 7,40 assesses visuospatial learning and delayed recall. In the 10/36 test, patients are presented a random pattern of 10 circles displayed on a 6 6 checkerboard for 10 seconds. They must then remember and reproduce that display by placing checkers on a blank checkerboard. This process is repeated for 3 learning trials, with an additional recall after a 7-minute delay. Scores are the total number of correct immediate recall responses across the 3 trials and delayed recall. Symbol Digit Modalities Test The Symbol Digit Modalities Test is designed to measure perceptual processing and attention. The patient is presented a form with a symbol/digit key containing 9 different symbols in the upper boxes paired with numbers (1-9) in the lower boxes. Beneath the key, patients are presented only the symbols, to which they must match the numbers indicated in the key. The patient has 90 seconds to match as many digit/ symbol pairs as possible. Scores are the number of correct responses in 90 seconds. Paced Auditory Serial Addition Test The Paced Auditory Serial Addition Test 30,41 measures information processing speed and sustained attention. This serial addition task requires the patient to listen to a series of singledigit numbers presented on a prerecorded tape, 61 numbers total. Number presentation occurs at a rate of 1 number every 3 seconds. The patient is instructed to add the first 2 numbers, to report the answer, and then to add the following number to the previous number (ie, sum the 2 numbers spoken in a row). In the second part of the task, numbers are presented more rapidly, at the rate of 1 number every 2 seconds, increasing information processing demands. For both conditions, practice items are administered before formal test initiation to ensure that patients are familiar with and able to successfully perform task demands. Scores are the number of correct responses for each test condition, with a maximum of 60 correct answers at each presentation rate (2 seconds and 3 seconds). Word List Generation Test This test measures semantic retrieval and production. The patient is asked to produce, within 60 seconds, as many words as possible beginning with a specified letter, excluding proper names, numbers, and multiple forms of a word. Scores are the sum of admissible responses across 3 trials. STATISTICAL ANALYSES Of 251 randomized patients, 248 agreed to participate in the neuropsychologic testing protocol. Primary statistical analyses were performed according to the intention-totreat principle and included all 248 patients. The lastobservation-carried-forward imputation strategy was used for missing data. Secondary analyses were performed that included only patients having the response variable of interest at all 3 visits (baseline, 12 months, and 24 months). Results did not differ between the 2 analyses; therefore, only results of the intention-to-treat analyses are reported. Repeated-measures analysis of covariance models were used to compare the placebo and glatiramer groups with regardtomeanneuropsychologictestscoresat12and24months. Separate analyses were performed for each neuropsychologic test. The models included treatment group, center, baseline neuropsychologic test score as a between-patient factor, and time as a within-patient factor. F tests were performed for significance of treatment effects, and 95% confidence intervals for these effects were computed using these models. In addition, F tests were performed for within-patient differences in mean performance over time in the combined cohort. Finally, exploratory analyses were performed to examine possible interactionsbetweentreatmentand(1) timeand(2) baselineneuropsychologic test scores, ie, to determine whether the effects of glatiramer therapy depended on either time or the severity of cognitive impairment at baseline. RESULTS BASELINE NEUROPSYCHOLOGIC TEST RESULTS At baseline testing, neuropsychologic test performance was similar in both treatment groups (Table 2). Mean scores were lower than established norms but not greater then 2 SDs below the mean and therefore were considered to be within the range of normal performance. The exception was Word List Generation Test scores, which showed impairment ( 2 SDs below the mean) in both treatment groups (Table 2). 45 RESPONSE TO TREATMENT Mean neuropsychologic test scores were improved at 12 and 24 months compared with baseline for the placebo and glatiramer groups (Table 2). The improvement over time was statistically significant (P.002) for the consistent long-term retrieval, delayed recall, and long-term storage components of the Buschke Selective Reminding Test; the 10/36 Spatial Recall Test; and the Paced Auditory Serial Addition Test. The Symbol Digit Modalities Test (P =.04) and the Word List Generation Test (P =.08) showed trends toward improvement over time. Table 3 presents the estimated treatment effects and associated 95% confidence intervals. No differences were detected between the treatment groups for any of the neuropsychologic test results. No significant interactions were detected between the effects of treatment and either time or baseline level of impairment. COMMENT Thisisthefirstlarge-scalestudytodeterminewhetheratreatment used to alter the course of MS affects cognitive function. Despite clear evidence of improvement in other measures of disease activity, such as relapse rate and neurologic disability, we found no effect of glatiramer therapy on the course of cognitive impairment in relapsing-remitting MS. 321
4 Neurologic and cognitive deficits are not strongly associated with each other in patients with MS, and outcome measures for these features have different degrees of sensitivity for impairment and therapeutic effects. Thus, it is possible that use of glatiramer truly had an effect on neurologic function but not on cognitive function, but the data do not support definitive conclusions. First, without a measurable decline in cognitive function in patients treated with placebo, there was no opportunity for glatiramer to demonstrate a therapeutic effect by minimizing that decline. Instead, both groups demonstrated improvement over time, with significant changes on measures of memory and attention. Although alternate test forms were used in an attempt to Table 1. Baseline Demographic Characteristics* Characteristic Glatiramer (n = 125) Treatment Placebo (n = 126) Age, y 34.6 ± ± 6.5 Sex Women 88 (70.4) 96 (76.2) Men 37 (29.6) 30 (23.8) Race White 118 (94.4) 118 (93.6) Other 7 (5.6) 8 (6.3) Previous 2-y relapse rate 2.9 ± ± 1.1 EDSS score 2.8 ± ± 1.3 Ambulation Index 1.2 ± ± 0.9 Duration of MS, y 7.3 ± ± 5.1 *EDSS indicates Expanded Disability Status Scale; MS, multiple sclerosis. Values are expressed as either mean ± SD or number (percentage). minimize practice effects, procedural learning, familiarity, and comfort with the testing procedure may explain improved performance. Also, a beneficial effect from the extra care, attention, and supportive social contact incurred during this study may have improved the overall performance in both groups. Second, patients were generally unimpaired at baseline in terms of overall cognitive performance. It could be that the effects of glatiramer administration are apparent only in patients who have a certain degree of initial baseline impairment. Our analyses of the interaction between treatment and baseline status did not reveal a dependence of the effect of glatiramer therapy on baseline performance. The subgroup of patients with impaired performance at baseline, however, was relatively small, thus limiting the power to detect differential treatment effects. Third, it could be that the effects of glatiramer therapy are not discernible during 24 months with this testing battery in this patient population. Little is known about the natural history of cognitive changes in MS. Only a few longitudinal investigations have been undertaken to address this question. Findings have been mixed, with some results showing cognitive decline and others showing no progressive worsening. Mariani et al 46 followed up 19 patients with relapsing-remitting MS for 2 years and found no progressive worsening of cognitive function and no association between cognitive and magnetic resonance imaging (MRI) changes. Another study by Amato et al, 47 following up patients with relapsing-remitting MS for 4 years, did not show worsening on measures of verbal memory and abstract reasoning measures beyond the initial baseline deficits. By the end of the study, however, new semantic retrieval deficits emerged. Table 2. Cognitive Test Results by Treatment Group and Visit* Test Treatment Group Visit Baseline 12 mo 24 mo Reference Value 10/36 Spatial Recall Immediate recall Glatiramer ± ± ± Placebo ± ± ± Delayed recall Glatiramer 7.32 ± ± ± Placebo 7.11 ± ± ± Paced Auditory Serial Addition 3 s Glatiramer ± ± ± ± Placebo ± ± ± s Glatiramer ± ± ± ± Placebo ± ± ± Symbol Digit Modalities Glatiramer ± ± ± ± Placebo ± ± ± Word List Generation Glatiramer ± ± ± ± Placebo ± ± ± Buschke Selective Reminding Consistent long-term retrieval Glatiramer ± ± ± ± Placebo ± ± ± Delayed recall Glatiramer 8.46 ± ± ± Placebo 8.46 ± ± ± Long-term storage Glatiramer ± ± ± ± Placebo ± ± ± *Values are given as mean ± SD. No differences were detected between the glatiramer and placebo groups on any of the neuropsychological tests. Mean scores improved over time on all tests. Average performance in healthy adults. Ellipses indicate not established. 322
5 Table 3. Effects of Glatiramer Treatment on Neuropsychologic Test Scores* Test Treatment Effect (95% Confidence Interval) P 10/36 Spatial Recall Immediate recall 0.15 ( 0.82 to 1.11).77 Delayed recall 0.08 ( 0.35 to 0.50).73 Paced Auditory Serial Addition 3 s 0.32 ( 1.74 to 1.10).66 2 s 1.17 ( 0.39 to 2.74).14 Symbol Digit Modalities 0.52 ( 2.50 to 1.45).60 Word List Generation 0.17 ( 1.28 to 1.63).81 Buschke Selective Reminding Consistent long-term retrieval 1.77 ( 4.36 to 0.81).18 Delayed recall 0.32 ( 0.78 to 0.13).16 Long-term storage 1.17 ( 3.50 to 1.15).32 *Treatment effects are estimated from repeated-measures analysis of variance models, which include treatment group, center, and baseline value of the neuropsychologic test of interest. See the text for details. Positive values indicate a beneficial effect of glatiramer acetate treatment relative to placebo treatment. Measurable cognitive deterioration over time was found in patients with a different MS disease course (formally known as chronic-progressive MS) when followed up from initial diagnosis for 4.5 years. 48 Feinstein et al 49 further studied cognitive and MRI changes in 5 patients with relapsing-remitting MS and 5 patients with long-term benign MS for 6 months and found 3 patients with increased MRI lesions, 2 of whom showed cognitive decline. Variable findings among these studies may be caused by differences in MS disease classification, length of followup, level of baseline impairment, and choice of cognitive test measures. The recent study by Hohol et al 50 of 44 patients with MS (relapsing-remitting, relapsingremitting-progressive, and chronic-progressive primary and secondary) attempted to account for some of these variables by studying the relationship between cognitive dysfunction and disease burden as measured by MRI for 1 year. The neuropsychologic test battery used in that study was the same battery used in our 2-year longitudinal investigation with glatiramer therapy. Their findings showed a similar pattern of long-term cognitive change, that is, during 1 year, cognitive performance did not worsen. Instead, verbal and nonverbal memory showed minor but significant improvement. They were able to show an association at 1 year between measures of attention of processing speed and MRI lesion burden, and the 4 patients who had cognitive worsening showed significant MRI changes. It is possible that changes in the study design of clinical trials in MS might allow us to observe otherwise undetectable cognitive change, allowing clearer interpretation of treatment effects. Design features that could be altered include selection of patients with greater cognitive impairment at baseline, a longer treatment interval to allow a measurable decline to occur, inclusion of level of education to ensure no academic differences between groups, and choosing neuropsychologic tests that are more sensitive to within-patient longitudinal changes. Despite the inconclusive results of this trial, emerging treatments for MS should continue to be examined for their effect on cognitive impairment because it can be a critical determinant of disability. Greater understanding of the natural history of cognitive decline in MS would be invaluable in the rational design of these trials. Accepted for publication July 10, This study was supported by Teva Pharmaceutical Industries Ltd, Petah Tiqva, Israel. Presented in part at the annual meeting of the American Neurological Association, San Diego, Calif, September 30, 1997, and the International Neuropsychological Society Meeting, Honolulu, Hawaii, February 5, The following investigators participated at the 11 sites involved in this study: K. P. Johnson, MD, and H. S. Panitch, MD (University of Maryland, Baltimore); B. R. Brooks, MD (University of Wisconsin, Madison); J. A. Cohen, MD (University of Pennsylvania, Philadelphia); C. C. Ford, MD (University of New Mexico, Albuquerque); J. Goldstein, MD, and T. Vollmer, MD (Yale University, New Haven, Conn); R. P. Lisak, MD (Wayne State University, Detroit, Mich); L. W. Myers, MD (University of California, Los Angeles); J. W. Rose, MD (University of Utah and the Veterans Administration Medical Center, Salt Lake City); R. B. Schiffer (University of Rochester, Rochester, NY); L. P. Weiner, MD (University of Southern California, Los Angeles); and J. S. Wolinsky, MD (University of Texas, Houston). Reprints: Amy Weinstein, PhD, Department of Neurology, University of Rochester Medical Center, PO Box 605, 601 Elmwood Ave, Rochester, NY ( aweinstein@mail.neurology.rochester.edu). REFERENCES 1. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45: Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33: Heaton RK, Nelson LM, Thompson DS, Burks JS, Franklin GM. Neuropsychological findings in relapsing-remitting and chronic progressive multiple sclerosis. J Consult Clin Psychol. 1985;53: Lyon-Caen O, Jouvert R, Hauser S, et al. Cognitive function in recent onset demyelinating diseases. Arch Neurol. 1986;43: Parsons OA, Stewart KD, Arenberg D. Impairment of abstracting ability in multiple sclerosis. J Nerv Ment Dis. 1957;125: Peyser JM, Edwards KR, Poser CM, Filskov SB. Cognitive function in patients with multiple sclerosis. Arch Neurol. 1980;37: Rao SM, Hammeke TA, McQuillen MP, Khatri BO, Loyd D. Memory disturbance in chronic progressive multiple sclerosis. Arch Neurol. 1984;41: Staples D, Lincoln NB. Intellectual impairment in multiple sclerosis and its relation to functional abilities. Rheumatol Rehab. 1979;18: Beatty WW, Goodkin DE, Monson N, Beatty PA, Hertsgaard D. Anterograde and retrograde amnesia in patients with chronic progressive multiple sclerosis. Arch Neurol. 1988;45: Carroll M, Gates R, Roldan F. Memory impairment in multiple sclerosis. Neuropsychologia. 1984;22: Fisher JS. Using the Wechsler Memory Scale-Revised to detect and characterize memory deficits in multiple sclerosis. Clin Neuropsychol. 1988;2: Grant I, McDonald WI, Trimble MR, Smith E, Reed R. Deficient learning and memory in early and middle phases of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1984;47: Litvan I, Graftnan J, Vendrell P, et al. Multiple memory deficits in patients with multiple sclerosis: exploring the working memory system. Arch Neurol. 1988; 45:
6 14. Minden SL, Moes EJ, Orav J, Kaplan E, Reich P. Memory impairment in multiple sclerosis. J Clin Exp Neuropsychol. 1990;12: Rao SM, Leo GJ, St. Aubin-Faubert P. On the nature of memory disturbance in multiple sclerosis. J Clin Exp Neuropsychol. 1989;11: Beatty WW, Goodkin DE, Monson N, Beatty PA. Cognitive disturbances in patients with relapsing-remitting multiple sclerosis. Arch Neurol. 1989;46: Litvan I, Graftnan J, Vendrell P, Martinez JM. Slowed information processing in multiple sclerosis. Arch Neurol. 1988;45: Rao SM, St. Aubin-Faubert P, Leo GJ. Information processing speed in patients with multiple sclerosis. J Clin Exp Neuropsychol. 1989;11: Caine ED, Bamford KA, Schiffer RB, Shoulson I, Levy S. A controlled neuropsychological comparison of Huntington s disease and multiple sclerosis. Arch Neurol. 1986;43: Huber SJ, Paulson GW, Shuttleworth EC, et al. Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch Neurol. 1987;44: Rao SM, Hammeke TA, Speech TJ. Wisconsin Card Sorting Test performance in relapsing-remitting and chronic-progressive multiple sclerosis. J Consult Clin Psychol. 1987;55: Rao SM, Hammeke TA. Hypothesis testing in patients with chronic progressive multiple sclerosis. Brain Cogn. 1984;3: Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis, I: frequency, patterns, and prediction. Neurology. 1991;41: Ron MA, Callanan MM, Warrington EK. Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study. Psychol Med. 1991;21: Ivnik RJ. Neuropsychological test performance as a function of the duration of MS related symptomatology. J Clin Psychiatry. 1978;39: Marsh GG. Disability and intellectual function in multiple sclerosis patients. J Nerv Ment Dis. 1980;168: Van den Burg W, Van Zomeren AH, Minderhoud JM, Prange M, Meijer NS. Cognitive impairment in patients with multiple sclerosis and mild physical disability. Arch Neurol. 1987;44: Young AC, Saunders J, Ponsford JR. Mental change as an early feature of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1976;39: Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis, II: impact on employment and social functioning. Neurology. 1991;41: Gronwall D. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills. 1977;44: Franklin GM, Nelson LM, Filley CM, Heaton RK. Cognitive loss in multiple sclerosis: case reports and review of the literature. Arch Neurol. 1989;46: Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in MS patients receiving interferon beta-1b. Neurology. 1996;47: Smits RC, Emmen HH, Bertelsmann FW, Kulig BM, Van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology. 1994;44: Peyser JM, Poser CM. Neuropsychological correlates of multiple sclerosis. In: Filskov SB, Boll TJ, eds. Handbook of Clinical Neuropsychology. New York, NY: John Wiley & Sons Inc; 1986: Peyser JM, Rao SM, LaRocca NG, Kaplan E. Guidelines for neuropsychological research in multiple sclerosis. Arch Neurol. 1990;47: Rao SM. Neuropsychology of multiple sclerosis: a critical review. J Clin Exp Neuropsychol. 1986;8: Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav. 1973;12: Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24: Kraemer HC, Peabody CA, Tinklenberg JR, Yesavage J. Mathematical and empirical development of a test of memory for clinical and research use. Psychol Bull. 1983;94: Barbizet J, Cany E. Clinical and psychometrical study of a patient with memory disturbances. Int J Neurol. 1968;7: Gronwall D, Wrightson P. Recovery after minor head injury. Lancet. 1974;2: Stuss DT, Stethem LL, Pelchat G. Three tests of attention and rapid information processing: an extension. Clin Neuropsychol. 1988;2: Lezak MD. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford University Press Inc; 1995: Rao SM. Cognitive Function Study Group, National Multiple Sclerosis Society. A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. New York, NY: National Multiple Sclerosis Society; Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City, Iowa: MA Associates; Mariani C, Farina E, Cappa SF, Mattioli F, Vignolo LA. Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging. J Neurol. 1991;238: Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Alnaducci L. Cognitive impairment in early-onset multiple sclerosis: pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol. 1995;52: Feinstein A, Youl B, Ron M. Acute optic neuritis: a cognitive and magnetic resonance imaging study. Brain. 1992;115: Feinstein A, Ron M, Thompson A. A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis. Brain. 1993;116: Hohol MJ, Guttman CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997; 54:
7 and CCK B receptor polymorphisms with alcohol dependence. Psychiatry Res. 2001; 102: Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, Neurology. 1999; 52: Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson s disease. Am J Epidemiol. 2003;157: Fernandez HH, Lapane KL, Ott BR, et al. Gender differences in the frequency and treatment of behavior problems in Parkinson s disease. Mov Disord. 2000; 15: Harada S, Okubo T, Tsutsumi M, Takase S, Muramatsu T. A new genetic variant in the Sp1 binding cis-element of cholecystokinin gene promoter region and relationship to alcoholism. Alcohol Clin Exp Res. 1998;22(suppl):93S-96S. 19. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson s disease. Neurology. 2001;57: Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson s disease. J Neurol Neurosurg Psychiatry. 1999;67: Studler JM, Javoy-Agid F, Cesselin F, et al. CCK-8 immunoreactivity distribution in human brain. Brain Res. 1982;243: Hansen TVO. Cholecystokinin gene transcription: promoter elements, transcription factors and signaling pathways. Peptides. 2001;22: Tachikawa H, Harada S, Kawanishi Y, et al. Novel polymorphisms of the human cholecystokinin A receptor gene. Am J Med Genet. 2000;96: Okubo T, Harada S. Polymorphisms of the CCK, CCKAR, and CCKBR genes: an association with alcoholism study. J Stud Alcohol. 2001;62: Wang Z, Valdes J, Noyes R, et al. Possible association of a cholecystokinin promoter polymorphism (CCK-36CT) with panic disorder. Am J Med Genet. 1998; 81: Bowen T, Norton N, Jacobsen NJO, et al. Linked polymorphisms upstream of exon 1 and exon 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder. Mol Psychiatry. 1998;3: Correction Error in Author Name. In the article titled Neuropsychologic Status in Multiple Sclerosis After Treatment With Glatiramer, published in the March issue of the ARCHIVES (1999;56: ), the author names should have appeared as follows: Amy Weinstein, PhD; Steven R. Schwid, MD; Randolph B. Schiffer, MD; Michael P. McDermott, PhD; Daniel W. Giang, MD; Andrew D. Goodman, MD. The ARCHIVES regret the error. (REPRINTED) ARCH NEUROL / VOL 61, AUG American Medical Association. All rights reserved.
Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves
744 SHORT REPORT Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves A Achiron, M Polliack, S M Rao, Y Barak, M Lavie, N Appelboim, Y Harel... Background
More informationORIGINAL CONTRIBUTION. Genetic Polymorphisms in Parkinson Disease Subjects With and Without Hallucinations
ORIGINAL CONTRIBUTION Genetic Polymorphisms in Parkinson Disease Subjects With and Without Hallucinations An Analysis of the Cholecystokinin System Jennifer G. Goldman, MD; Christopher G. Goetz, MD; Elizabeth
More informationAdaptational Approach to Cognitive Rehabilitation in Multiple Sclerosis: Description of Three Models of Care
Adaptational Approach to Cognitive Rehabilitation in Multiple Sclerosis: Description of Three Models of Care Päivi Hämäläinen, PhD; Arja Seinelä, MA; Juhani Ruutiainen, MD Masku Neurological Rehabilitation
More informationPlenary Session 2 Psychometric Assessment. Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo
Plenary Session 2 Psychometric Assessment Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo Reliability Validity Group Discrimination, Sensitivity Validity Association
More informationImpairments in cognitive abilities are among the. Promising New Approaches to Assess Cognitive Functioning in People with Multiple Sclerosis
Promising New Approaches to Assess Cognitive Functioning in People with Multiple Sclerosis Heather Becker, PhD; Alexa Stuifbergen, PhD, RN, FAAN; Janet Morrison, MSN, RN Cognitive impairment has a major
More informationA randomised, placebo-controlled trial investigating the role of Fampridine in cognitive performance of patients with multiple sclerosis.
A randomised, placebo-controlled trial investigating the role of Fampridine in cognitive performance of patients with multiple sclerosis. PRINCIPAL INVESTIGATOR: Name: Carlo Pozzilli Institution/Organization:
More informationClinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and
J7ournal of Neurology, Neurosurgery, and Psychiatry 1992;55:869-876 National Hospital for Neurology and Neurosurgery and Institute of Neurology, London A Feinstein L D Kartsounis D H Miller M A Ron Institute
More informationPrevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis
SHORT REPORT Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Giulia DiGiuseppe, BSc; Mervin Blair, PhD; Sarah A. Morrow, MD Background: Cognitive impairment
More informationCognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis. Background
Cognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis Victoria A Levasseur 1,2, Samantha Lancia 1, Gautam Adusumilli 1, Zach Goodman 1, Stuart D. Cook 3, Diego Cadavid 4, Robert T.
More informationRegional MRI lesion burden and cognitive function in MS: A longitudinal study
Regional MRI lesion burden and cognitive function in MS: A longitudinal study Sperling RA, Guttmann CRG, Hohol MJ, Warfield SK, Jakab M, Parente M, Diamond EL, Daffner KR, Olek MJ, Orav EJ, Kikinis R,
More informationVisual perception and hand function in persons with multiple sclerosis
194 Occupational Therapy International, 5(3), 194 205, 1998 Whurr Publishers Ltd Visual perception and hand function in persons with multiple sclerosis ANNA LAU and CHETWYN C.H. CHAN, Department of Rehabilitation
More informationC ognitive problems are common in patients with
PAPER Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis N B Lincoln, A Dent, J Harding, N Weyman, C Nicholl, L D Blumhardt E D Playford... See end of article
More informationAnxiety and Depressive Symptoms Are Associated With Worse Performance on Objective Cognitive Tests in MS
ARTICLES This article addresses the Core Competency of Patient Care and Procedural Skills Anxiety and Depressive Symptoms Are Associated With Worse Performance on Objective Cognitive Tests in MS Sarah
More informationMR Lesion Load and Cognitive Function in Patients with Relapsing-Remitting Multiple Sclerosis
AJNR Am J Neuroradiol 20:11 1, November/December 1 MR Lesion Load and Cognitive Function in Patients with Relapsing-Remitting Multiple Sclerosis Jennifer C. Fulton, Robert I. Grossman, Jayaram Udupa, Lois
More informationTrail making test A 2,3. Memory Logical memory Story A delayed recall 4,5. Rey auditory verbal learning test (RAVLT) 2,6
NEUROLOGY/2016/790584 Table e-1: Neuropsychological test battery Cognitive domain Test Attention/processing speed Digit symbol-coding 1 Trail making test A 2,3 Memory Logical memory Story A delayed recall
More informationThe Use of Brief Assessment Batteries in Multiple Sclerosis. History of Cognitive Studies in MS
This is the html version of the file http://wwwvagov/ms/library/managing/robert_kane_brief_assessment_batteries_in_msppt Google automatically generates html versions of documents as we crawl the web 1
More informationAssessment of Memory
Journal of the K. S. C. N. Vol. 2, No. 2 Assessment of Memory Juhwa Lee Department of Neurology, College of Medicine, Kaemyung University - Abstract - The characteristics of human memory structure and
More informationRapidly-administered short forms of the Wechsler Adult Intelligence Scale 3rd edition
Archives of Clinical Neuropsychology 22 (2007) 917 924 Abstract Rapidly-administered short forms of the Wechsler Adult Intelligence Scale 3rd edition Alison J. Donnell a, Neil Pliskin a, James Holdnack
More informationExamining the Link between Information Processing Speed and Executive Functioning in Multiple Sclerosis
Archives of Clinical Neuropsychology 24 (2009) 47 58 Examining the Link between Information Processing Speed and Executive Functioning in Multiple Sclerosis Abstract Margaret A. Drew, Nicola J. Starkey*,
More informationTHE NEUROPSYCHOLOGY OF POST-POLIO FATIGUE. Richard L. Bruno, Thomas Galski, John DeLuca.
FROM The Post-Polio Institute and The International Centre for Post-Polio Education and Research postpolioinfo@aol.com Archives of Physical Medicine and Rehabilitation, 1993; 74: 1061-1065. THE NEUROPSYCHOLOGY
More informationCognitive Impairment Among Patients with Multiple Sclerosis. Associations with Employment and Quality of Life.
Cognitive Impairment Among Patients with Multiple Sclerosis. Associations with Employment and Quality of Life. J Campbell 1, W Rashid 2, M Cercignani 1, D Langdon 3. 1 Clinical Imaging Sciences Centre,
More informationExecutive function in multiple sclerosis The role of frontal lobe pathology
braini0102 Executive function in multiple sclerosis The role of frontal lobe pathology Brain (1997), 120, 15 26 J. Foong, 1 L. Rozewicz, 1 G. Quaghebeur, 2 C. A. Davie, 1 L. D. Kartsounis, 2 A. J. Thompson,
More informationORIGINAL CONTRIBUTION. Multiple Sclerosis That Is Progressive From the Time of Onset
ORIGINAL CONTRIBUTION Multiple Sclerosis That Is Progressive From the Time of Onset Clinical Characteristics and Progression of Disability P. B. Andersson, MBChB, DPhil; E. Waubant, MD; L. Gee, MPH; D.
More informationCognitive impairment is a prevalent concern in. Longitudinal Stability of Cognition in Early-Phase Relapsing-Remitting Multiple Sclerosis
Longitudinal Stability of Cognition in Early-Phase Relapsing-Remitting Multiple Sclerosis Does Cognitive Reserve Play a Role? Roxana M. Barbu, MCogSci; Jason A. Berard, BScH; Louise M. Gresham, BScH; Lisa
More informationMultiple sclerosis : how cognitive performance relates to quality of life, depression, and perception of deficits
Oregon Health & Science University OHSU Digital Commons Scholar Archive May 2011 Multiple sclerosis : how cognitive performance relates to quality of life, depression, and perception of deficits Rebecca
More informationSerial 7s and Alphabet Backwards as Brief Measures of Information Processing Speed
Pergamon Archives of Clinical Neuropsychology, Vol. 11, No. 8, pp. 651-659, 1996 Copyright 9 1996 National Academy of Neuropsychology Printed in the USA. All fights reserved 0887-6177/96 $15.00 +.00 PH
More informationMRI dynamics of brain and spinal cord in progressive multiple sclerosis
J7ournal of Neurology, Neurosurgery, and Psychiatry 1 996;60: 15-19 MRI dynamics of brain and spinal cord in progressive multiple sclerosis 1 5 D Kidd, J W Thorpe, B E Kendall, G J Barker, D H Miller,
More informationTest Assessment Description Ref. Global Deterioration Rating Scale Dementia severity Rating scale of dementia stages (2) (4) delayed recognition
Table S. Cognitive tests used in the Georgia Centenarian Study. Test Assessment Description Ref. Mini-Mental State Examination Global cognitive performance A brief screening of orientation, memory, executive
More informationTreatment of AD with Stabilized Oral NADH: Preliminary Findings
MS # 200 000 128 Treatment of AD with Stabilized Oral NADH: Preliminary Findings G.G. Kay, PhD, V. N. Starbuck, PhD and S. L. Cohan, MD, PhD Department of Neurology, Georgetown University School of Medicine
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationProcess of a neuropsychological assessment
Test selection Process of a neuropsychological assessment Gather information Review of information provided by referrer and if possible review of medical records Interview with client and his/her relative
More informationCRITICALLY APPRAISED PAPER
CRITICALLY APPRAISED PAPER FOCUSED QUESTION For individuals with memory and learning impairments due to traumatic brain injury, does use of the self-generation effect (items self-generated by the subject)
More informationTable 1: Summary of measures of cognitive fatigability operationalised in existing research.
Table 1: Summary of measures of cognitive fatigability operationalised in existing research. Candidate Mmeasures Studies Procedure Self-reported fatigue measure Key Findings The auditory As and auditory
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationA longitudinal study of cognition in primary progressive multiple sclerosis
doi:10.1093/brain/awh602 Brain (2005), 128, 2891 2898 A longitudinal study of cognition in primary progressive multiple sclerosis S. J. Camp, 1 V. L. Stevenson, 1 A. J. Thompson, 1 G. T. Ingle, 1 D. H.
More informationWPE. WebPsychEmpiricist
McKinzey, R. K., Podd, M., & Kreibehl, M. A. (6/25/04). Concurrent validity of the TOMM and LNNB. WebPsychEmpiricist. Retrieved (date), from http://wpe.info/papers_table.html WPE WebPsychEmpiricist Concurrent
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationCOGNITIVE AND BRAIN CHANGES IN MULTIPLE SCLEROSIS
1 COGNITIVE AND BRAIN CHANGES IN MULTIPLE SCLEROSIS MARCH 27, 2017 Esther Fujiwara, Ph.D. (efujiwara@ualberta.ca) Department of Psychiatry, University of Alberta 2 Objectives 1. Identify cognitive challenges
More informationChanging EDSS progression in placebo cohorts in relapsing MS:
Changing EDSS progression in placebo cohorts in relapsing MS: A systematic review and meta-regression Christian Röver 1, Richard Nicholas 2, Sebastian Straube 3, Tim Friede 1 1 Department of Medical Statistics,
More informationProceedings of the Annual Meeting of the American Statistical Association, August 5-9, 2001
Proceedings of the Annual Meeting of the American Statistical Association, August 5-9, 1 SCREENING FOR DEMENTIA USING LONGITUDINAL MEASUREMENTS OF COGNITION Christopher H. Morrell, Mathematical Sciences
More informationGlobal N-acetyl aspartate correlates with. cognitive dysfunction in multiple sclerosis
Global N-acetyl aspartate correlates with cognitive dysfunction in multiple sclerosis 1 Henrik Kahr Mathiesen, MD; 2 Agnete Jonsson, Psychologist; 2 Thomas Tscherning, MD; 1 Lars G. Hanson, Physicist,
More informationMost patients with multiple sclerosis (MS) experience a
Cognitive Function in Patients with Multiple Sclerosis: Impairment and Treatment Stephen M. Rao, PhD Cognitive impairment is common in multiple sclerosis (MS), with up to 65% of patients exhibiting some
More informationLong-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation
Boyko Multiple Sclerosis and Demyelinating Disorders (2016) 1:14 DOI 10.1186/s40893-016-0015-x Multiple Sclerosis and Demyelinating Disorders RESEARCH ARTICLE Open Access Long-term results of the first
More informationMedscape: What do you see as the main clinical implications of your results?
http://www.medscape.com/px/viewindex/more?bucket=columns§ionid=2011 Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD Posted 11/10/2004 Editor's Note: Multiple
More informationMeasurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History
Measurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History Group Means for NP and MMPI Variables N=381 Consecutive
More informationNature, prevalence and clinical significance. Barcelona, Spain
Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationUsing contextual analysis to investigate the nature of spatial memory
Psychon Bull Rev (2014) 21:721 727 DOI 10.3758/s13423-013-0523-z BRIEF REPORT Using contextual analysis to investigate the nature of spatial memory Karen L. Siedlecki & Timothy A. Salthouse Published online:
More informationCarmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation
Carmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation Neuropsychological Tests Battery The following List represents
More informationNeuropsychological Testing (NPT)
Neuropsychological Testing (NPT) POLICY Psychological testing (96101-03) refers to a series of tests used to evaluate and treat an individual with emotional, psychiatric, neuropsychiatric, personality
More informationQuality of life in multiple sclerosis: Does information-processing speed have an independent effect?
Archives of Clinical Neuropsychology 21 (2006) 167 174 Quality of life in multiple sclerosis: Does information-processing speed have an independent effect? Suzanne L. Barker-Collo Department of Psychology,
More informationResearch Article Assessment of Early Cognitive Impairment in Patients with Clinically Isolated Syndromes and Multiple Sclerosis
Behavioural Neurology, Article ID 637694, 5 pages http://dx.doi.org/1.1155/214/637694 Research Article Assessment of Early Cognitive Impairment in Patients with Clinically Isolated Syndromes and Multiple
More informationThe New England Journal of Medicine A POPULATION-BASED STUDY OF SEIZURES AFTER TRAUMATIC BRAIN INJURIES
A POPULATION-BASED STUDY OF SEIZURES AFTER TRAUMATIC BRAIN INJURIES JOHN F. ANNEGERS, PH.D., W. ALLEN HAUSER, M.D., SHARON P. COAN, M.S., AND WALTER A. ROCCA, M.D., M.P.H. ABSTRACT Background The risk
More informationEveryday Problem Solving and Instrumental Activities of Daily Living: Support for Domain Specificity
Behav. Sci. 2013, 3, 170 191; doi:10.3390/bs3010170 Article OPEN ACCESS behavioral sciences ISSN 2076-328X www.mdpi.com/journal/behavsci Everyday Problem Solving and Instrumental Activities of Daily Living:
More informationInvestor Update. Basel, 23 April 2018
Investor Update Basel, 23 April 2018 New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis Four years of
More informationResearch Article Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
Hindawi Behavioural Neurology Volume 2017, Article ID 7404289, 10 pages https://doi.org/10.1155/2017/7404289 Research Article Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with
More informationMEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease
MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still
More informationNeuropsychological Test Development and Normative Data on Hispanics
Archives of Clinical Neuropsychology, Vol. 14, No. 7, pp. 593 601, 1999 Copyright 1999 National Academy of Neuropsychology Printed in the USA. All rights reserved 0887-6177/99 $ see front matter PII S0887-6177(99)00008-6
More informationConcurrent validity of WAIS-III short forms in a geriatric sample with suspected dementia: Verbal, performance and full scale IQ scores
Archives of Clinical Neuropsychology 20 (2005) 1043 1051 Concurrent validity of WAIS-III short forms in a geriatric sample with suspected dementia: Verbal, performance and full scale IQ scores Brian L.
More informationConfusional state. Digit Span. Mini Mental State Examination MMSE. confusional state MRI
10 304 29 3 confusional state MRI 29 3 304 311 2009 Key Words memory test attention brain region causative disease subcortical dementia 1 Confusional state Digit Span 1 1 5 4 Mini Mental State Examination
More informationA longitudinal study of cognitive changes in MS dimensionality, predictors and selfperception
This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions
More informationNICE appraisal consultation document for teriflunomide [ID548]
NICE appraisal consultation document for teriflunomide [ID548] Response from the Multiple Sclerosis Trust 9 th October 2013 Please find below comments from the MS Trust in relation to the Appraisal Consultation
More informationInnovazione e personalizzazione nella terapia della SM. Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila
Innovazione e personalizzazione nella terapia della SM Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila Which are the objectives of MS treatment? «Historically»
More informationORIGINAL ARTICLE EUROPEAN JOURNAL OF NEUROLOGY. Introduction
ORIGINAL ARTICLE Natalizumab improves ambulation in relapsing remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM N. Voloshyna a, E. Havrdova b,
More informationTraumatic Brain Injury for VR Counselors Margaret A. Struchen, Ph.D. and Laura M. Ritter, Ph.D., M.P.H.
Training Session 3a: Understanding Roles of Members of the Interdisciplinary Treatment Team, Evaluations by Team Members and the Utility of Evaluations Conducted by such Team Members. The Interdisciplinary
More informationRunning head: CPPS REVIEW 1
Running head: CPPS REVIEW 1 Please use the following citation when referencing this work: McGill, R. J. (2013). Test review: Children s Psychological Processing Scale (CPPS). Journal of Psychoeducational
More informationCognitive rehabilitation: assessment. Dawn Langdon PhD
Cognitive rehabilitation: assessment Dawn Langdon PhD 1 Assessment for cognitive rehabilitation Patient context Individual Family Work Insight Mood Motivation Observation of patient performance Rehabilitation
More informationInterpreting change on the WAIS-III/WMS-III in clinical samples
Archives of Clinical Neuropsychology 16 (2001) 183±191 Interpreting change on the WAIS-III/WMS-III in clinical samples Grant L. Iverson* Department of Psychiatry, University of British Columbia, 2255 Wesbrook
More informationReach2HD Phase 2 Clinical Trial Top Line Results. Investor Conference Call 19 th February 2014
Reach2HD Phase 2 Clinical Trial Top Line Results Investor Conference Call 19 th February 2014 Safe Harbour This presentation may contain some statements that may be considered Forward-Looking Statements,
More informationPhysostigmme in Alzheimer s Disease
Effects of Oral Physostigmme in Alzheimer s Disease Yaakov Stern, PhD,? Mary Sano, PhD,* and hchard Mayeux, MD t Previous studies of oral physostigmine in the treatment of Alzheimer s disease have: (1)
More informationTHE CLINICAL course of severe
ORIGINAL ARTICLE Improved Prediction of Outcome in Patients With Severe Acute Pancreatitis by the APACHE II Score at 48 Hours After Hospital Admission Compared With the at Admission Arif A. Khan, MD; Dilip
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationA cost utility model of interferon beta-1b in the treatment of relapsing-remitting multiple sclerosis Phillips C J, Gilmour L, Gale R, Palmer M
A cost utility model of interferon beta-1b in the treatment of relapsing-remitting multiple sclerosis Phillips C J, Gilmour L, Gale R, Palmer M Record Status This is a critical abstract of an economic
More informationNovartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis real-world data at AAN confirms
More informationResearch Article Impact of Depression, Fatigue, and Global Measure of Cortical Volume on Cognitive Impairment in Multiple Sclerosis
BioMed Research International Volume 2015, Article ID 519785, 7 pages http://dx.doi.org/10.1155/2015/519785 Research Article Impact of Depression, Fatigue, and Global Measure of Cortical Volume on Cognitive
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationDetecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors?
Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors? Jennifer Lewis, PsyD; Mathew Hirsch, PsyD & Susan Abramowitz, PhD NYU School of Medicine, New York, NY Friday,
More informationAPPENDIX A TASK DEVELOPMENT AND NORMATIVE DATA
APPENDIX A TASK DEVELOPMENT AND NORMATIVE DATA The normative sample included 641 HIV-1 seronegative gay men drawn from the Multicenter AIDS Cohort Study (MACS). Subjects received a test battery consisting
More informationClinical Study Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis International Volume 23, Article ID 89624, 9 pages http://dx.doi.org/.55/23/89624 Clinical Study Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple
More informationChapter Two Incidence & prevalence
Chapter Two Incidence & prevalence Science is the observation of things possible, whether present or past. Prescience is the knowledge of things which may come to pass, though but slowly. LEONARDO da Vinci
More informationResearch Article Does Fatigue Complaint Reflect Memory Impairment in Multiple Sclerosis?
Multiple Sclerosis International, Article ID 692468, 6 pages http://dx.doi.org/10.1155/2014/692468 Research Article Does Fatigue Complaint Reflect Memory Impairment in Multiple Sclerosis? Caroline Jougleux-Vie,
More informationAFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE
AFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE INTENDED USE The information in this module is being provided to you to increase your knowledge and understanding of the AFFIRM a study. Although this
More informationClarence Liu, Lance D Blumhardt. in trial disability in patients with multiple sclerosis with fluctuating and highly heterogeneous
J Neurol Neurosurg Psychiatry 999;67:45 456 45 Division of Clinical Neurology, Department of Medicine, University Hospital, Queen s Medical Centre, Nottingham NG7 UH, UK C Liu L D Blumhardt Correspondence
More informationEmpire BlueCross BlueShield Professional Commercial Reimbursement Policy
Subject: Documentation Guidelines for Central Nervous System Assessments and Tests NY Policy: 0046 Effective: 12/01/2014 11/30/2015 Coverage is subject to the terms, conditions, and limitations of an individual
More informationLongitudinal Assessment of Health-Related Quality of Life (HRQL) of Patients With Multiple Sclerosis
Longitudinal Assessment of Health-Related Quality of Life (HRQL) of Patients With Multiple Sclerosis Wilma M. Hopman, MA; Helen Coo, MSc; Donald G. Brunet, MD; Catherine M. Edgar, BNSc, RN; and Michael
More informationInternational Forum on HIV and Rehabilitation Research
Neurocognitive screening and behavioural interventions for HIV-Associated Neurocognitive Disorders (HAND) International Forum on HIV and Rehabilitation Research Translating Research Evidence from the Canada-UK
More information21/05/2018. Today s webinar will answer. Presented by: Valorie O Keefe Consultant Psychologist
Today s webinar will answer. 1. What is the RBANS, and how is the updated version different than the original version? 2. What are the neurocognitive areas assessed by the RBANS and what scores are available?
More informationINFORMATION PROCESSING IN MULTIPLE SCLEROSIS: ACCURACY VERSUS SPEED. Katherine A. Steiger
INFORMATION PROCESSING IN MULTIPLE SCLEROSIS: ACCURACY VERSUS SPEED by Katherine A. Steiger Submitted to the Graduate Program in Psychology, and to the Graduate Faculty of the University of Kansas in partial
More informationPrognosis: What happens in Transient Epileptic Amnesia: over TIME? Dr Sharon Savage
Prognosis: What happens in Transient Epileptic Amnesia: over TIME? Dr Sharon Savage s.a.savage@exeter.ac.uk TEA Day, June 2018 At onset, most commonly. (Butler et al., 2007) Common memory difficulties
More informationEveryday cognition in temporal lobe and frontal lobe epilepsy
Original article Epileptic Disord 2009; 11 (3): 222-7 Everyday cognition in temporal lobe and frontal lobe epilepsy Deborah A. Cahn-Weiner 1, Dana Wittenberg 1, Carrie McDonald 2 1 Department of Neurology,
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 9, 2013 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Ampyra (dalfampridine) Page 1 of 9 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Ampyra (dalfampridine) Prime Therapeutics will review Prior Authorization
More informationClinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets
494 Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute Ospedale San RaVaele, University of Milan, Via Olgettina 6, 2132 Milan, Italy M P Sormani M Rovaris M Filippi Clinical Trials
More informationQuality of life defined
Psychometric Properties of Quality of Life and Health Related Quality of Life Assessments in People with Multiple Sclerosis Learmonth, Y. C., Hubbard, E. A., McAuley, E. Motl, R. W. Department of Kinesiology
More informationGuideline for the use of beta-interferons in patients with multiple sclerosis a South African proposal
GUIDELINE Guideline for the use of beta-interferons in patients with multiple sclerosis a South African proposal Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA)
More informationCognitive screening tools in multiple sclerosis revisited: sensitivity and specificity of a short version of Rao s Brief Repeatable Battery
Hansen et al. BMC Neurology (2015) 15:246 DOI 10.1186/s12883-015-0497-8 RESEARCH ARTICLE Cognitive screening tools in multiple sclerosis revisited: sensitivity and specificity of a short version of Rao
More informationAuthor's response to reviews
Author's response to reviews Title: The Older People, Omega-3, and Cognitive Health (EPOCH) trial design and methodology: A randomised, double-blind, controlled trial investigating the effect of long-chain
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationDr. Prasanth Varghese C. Resident in Neurology. Month and Year of Submission: October 2013
Frequency and pattern of cognitive dysfunction in Multiple Sclerosis and correlation with MRI lesion load from a Tertiary Referral centre in South India Thesis submitted in partial fulfilment of the rules
More informationChapter 8: Visual Imagery & Spatial Cognition
1 Chapter 8: Visual Imagery & Spatial Cognition Intro Memory Empirical Studies Interf MR Scan LTM Codes DCT Imagery & Spatial Cognition Rel Org Principles ImplEnc SpatEq Neuro Imaging Critique StruEq Prop
More information